Sanofi (SNYNF)
OTCMKTS
· Delayed Price · Currency is USD
98.12
+0.47 (0.49%)
Aug 14, 2025, 12:16 PM EDT
Sanofi Revenue
Sanofi had revenue of 10.74B EUR in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to 45.74B, up 15.65% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 7.73% growth.
Revenue (ttm)
45.74B EUR
Revenue Growth
+15.65%
P/S Ratio
2.21
Revenue / Employee
551.87K EUR
Employees
82,878
Market Cap
118.83B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.17M |
| Global Cord Blood | 196.10M |
Sanofi News
- 7 days ago - Sanofi: Playing To Win - Seeking Alpha
- 7 days ago - Emcure Pharmaceuticals Reports Strong Q1 FY26 Results with 16% Revenue Growth and 41% Jump in Profit - Business Upturn
- 7 days ago - Novavax raises 2025 revenue target to $1.05B with milestone payments and streamlined expenses as Sanofi partnership progresses - Seeking Alpha
- 8 days ago - Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc. - GlobeNewsWire
- 10 days ago - What's Driving the Market Sentiment Around Sanofi? - Benzinga
- 13 days ago - Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges - WSJ
- 13 days ago - Arrowhead unit sells rights for plozasiran to Sanofi in Greater China - Seeking Alpha
- 13 days ago - European drugmakers fall after Trump raises stakes over US drug price cuts - Reuters